RHJA
RYTM icon

Rice Hall James & Associates’s Rhythm Pharmaceuticals RYTM Stock Holding History

Rice Hall James & Associates’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-93,081
Closed -$3.82M – 263
2024
Q2 		$3.82M Buy
93,081
+3,355
+4% +$134K 0.23% 99
2024
Q1 		$3.89M Buy
89,726
+121
+0.1% +$5.29K 0.22% 94
2023
Q4 		$4.12M Sell
89,605
-67,821
-43% -$2.14M 0.24% 96
2023
Q3 		$3.61M Sell
157,426
-1,533
-1% -$34.3K 0.23% 103
2023
Q2 		$2.62M Buy
158,959
+5,173
+3% +$93.4K 0.15% 149
2023
Q1 		$2.74M Buy
153,786
+584
+0.4% +$14.7K 0.16% 153
2022
Q4 		$4.46M Sell
153,202
-17,155
-10% -$441K 0.26% 93
2022
Q3 		$4.17M Buy
170,357
+11,357
+7% +$211K 0.24% 102
2022
Q2 		$660K Buy
159,000
+22,479
+16% +$123K 0.03% 238
2022
Q1 		$1.57M Buy
136,521
+8,975
+7% +$78.8K 0.06% 225
2021
Q4 		$1.27M Sell
127,546
-22,174
-15% -$249K 0.05% 235
2021
Q3 		$1.96M Buy
149,720
+5,726
+4% +$87.4K 0.07% 208
2021
Q2 		$2.82M Buy
143,994
+79,733
+124% +$1.66M 0.1% 160
2021
Q1 		$1.37M Buy
64,261
+15,538
+32% +$451K 0.04% 239
2020
Q4 		$1.45M Sell
48,723
-5,868
-11% -$149K 0.05% 228
2020
Q3 		$1.18M Buy
54,591
+17,381
+47% +$398K 0.05% 223
2020
Q2 		$830K Sell
37,210
-24,704
-40% -$482K 0.04% 220
2020
Q1 		$942K Buy
61,914
+619
+1% +$11.1K 0.05% 202
2019
Q4 		$1.41M Sell
61,295
-3,509
-5% -$78K 0.05% 209
2019
Q3 		$1.4M Buy
64,804
+1,587
+3% +$34K 0.05% 211
2019
Q2 		$1.39M Buy
63,217
+40,015
+172% +$1.01M 0.05% 221
2019
Q1 		$636K Buy
+23,202
New +$667K 0.02% 262

Other funds holding RYTM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Rice Hall James & Associates's RYTM Position: Q3 2024 in Review

Rice Hall James & Associates sold out of Rhythm Pharmaceuticals (RYTM) in Q3 2024, closing a stake of 93,081 shares — an estimated $3.82M sold.

Rice Hall James & Associates first reported a position in RYTM in Q1 2019 and held it in 22 quarters. The position peaked at $4.46M in Q4 2022. 176 funds tracked by Wall St. Rank hold RYTM as of Q3 2024.

  • Rice Hall James & Associates reported no remaining Rhythm Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Rice Hall James & Associates sold 93,081 Rhythm Pharmaceuticals shares in Q3 2024, an estimated $3.82M.
  • Rice Hall James & Associates first reported a position in Rhythm Pharmaceuticals in Q1 2019 and held it in 22 quarters.
  • Rice Hall James & Associates's Rhythm Pharmaceuticals position peaked at $4.46M in Q4 2022.
  • 176 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q3 2024.

Based on Rice Hall James & Associates's 13F filing for Q3 2024, filed 28 Oct 2024.